This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The legacy product now lies outside Bayer’s core areas of cardiology, oncology, haematology, ophthalmology, women’s health and radiopharmaceuticals, and the funds raised from the sale will support the “ongoing transformation of Bayer’s pharma business to focus on key areas of future medical innovation”, said the company.
The Digital Health Academy – developed with pharmacompany Boehringer Ingelheim – is part of a drive to get digital health tools and apps used more routinely in the management of health conditions, according to ORCHA.
The heart and vascular medication market continues to be a critical focus area for pharmacompanies, with billions of dollars in sales generated annually. Their widespread adoption is driven by strong clinical evidence, broad FDA-approved indications and continued advancements in treatment protocols.
By most measures the single largest pharmacompany in the world, US-based Johnson & Johnson (J&J) is also arguably one of the most well-known drugmakers among the general public. . This move revolutionised cardiology – coronary stents keep vessels open so blood can flow to the heart.
Why Pharma Needs Email Marketing Direct Access to HCPs : Doctors, pharmacists, and researchers check their emails frequently for industry updates and medical advancements. Patient Education & Support : Email allows pharmacompanies to provide disease awareness, medication adherence tips, and product updates.
Wellthy developed partnerships with pharmacompanies across Europe & Asia, which Abhishek says is helping his company address unmet patient needs through digital health solutions. He provides insights into pharmacompanies’ structural changes and tips on telltale signs of good pharma partners.
XTALKS WEBINAR: Environmental Sustainability and the Supply of Medicines for Clinical Trials Live and On-Demand: Thursday, January 16, 2025, at 10am EST (4pm CET/EU-Central) Register for this free webinar to learn how major pharmacompanies are working towards environmental sustainability and reducing their environmental impact.
Major societies such as the European Society of cardiology (ESC) reported a 177% increase in attendees for its 2020 annual congress : 77,350 virtual attendees (logged-on) 2020 cf 27,946 physical attendees 2019. One important caveat here is that delegate registration fees were waived. About the author.
So, how can pharmacompanies use content marketing to engage HCPs and patients effectively ? Pharma brands can develop: Whitepapers on clinical trials showcasing drug effectiveness. Scientific blogs discussing new advancements in oncology, cardiology, or rare diseases. Lets dive in.
. “When you look at the combination of aspirin and the polypill, you definitely see a meaningful reduction in cardiovascular events,” said Dr. Eugene Yang, chair-elect of the American College of Cardiology’s Prevention of Cardiovascular Disease Council.
We did not get a Class II certification for diabetes only, or orthopedics or cardiology; we got a disease-agnostic certification. Now, as we develop new predictive algorithms, whether that is in diabetes, cardiology, respiratory or oncology, we can bring those algorithms to our platform because it is disease-agnostic.
By leveraging digital tools, content personalization, and interactive experiences, pharmacompanies can enhance engagement and build long-term relationships. This article explores effective audience engagement strategies tailored for pharma marketers, focusing on both HCPs and patients.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content